CDTX Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 21.47%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Johnson & Johnson's return on equity of 33.27%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.29%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.71%. Given that Johnson & Johnson has higher upside potential than Cidara Therapeutics, Inc., analysts believe Johnson & Johnson is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.461, which suggesting that the stock is 46.073% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 5.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 33.68%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Merck & Co., Inc.'s return on equity of 39.63%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.29%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 4.76%. Given that Merck & Co., Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.461, which suggesting that the stock is 46.073% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.12% to investors and pays a quarterly dividend of $0.85 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 4.14x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Mersana Therapeutics, Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of -68.54%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Mersana Therapeutics, Inc.'s return on equity of -533.43%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.29%. On the other hand Mersana Therapeutics, Inc. has an analysts' consensus of $33.20 which suggests that it could grow by 14.48%. Given that Mersana Therapeutics, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Mersana Therapeutics, Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.461, which suggesting that the stock is 46.073% more volatile than S&P 500. In comparison Mersana Therapeutics, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.856%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Mersana Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Mersana Therapeutics, Inc. quarterly revenues of $11M. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Mersana Therapeutics, Inc.'s net income of -$7.5M. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Mersana Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 56.38x for Mersana Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -30201.66% compared to Cidara Therapeutics, Inc.'s net margin of 21.32%. Cidara Therapeutics, Inc.'s return on equity of -68.74% beat Pfizer Inc.'s return on equity of 10.84%.

Cidara Therapeutics, Inc. has a consensus price target of $221.50, signalling upside risk potential of 0.29%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 15.04%. Given that Pfizer Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Cidara Therapeutics, Inc..

Cidara Therapeutics, Inc. has a beta of 1.461, which suggesting that the stock is 46.073% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Cidara Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Cidara Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Cidara Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Cidara Therapeutics, Inc.'s net income of -$83.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Cidara Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cidara Therapeutics, Inc. is 55.23x versus 2.26x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.